Pharmacist-Led Treat-to-Target Urate Lowering Therapy in Patients With Gout (NCT06887452)
Pharmacist-Led Treat-to-Target Urate Lowering Therapy in Patients in Gout (Pharm-UP) Study
🩺 Plain-English Summary (8th-Grade Level)
This study will compare two different approaches to manage medications that lower uric acid levels. This study will be conducted at five VA medical centers across the United States and will take 4-5 years to complete. Individual participation will last up to two years.
Who can join: Review the eligibility criteria below.
Location: Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE — Omaha, Nebraska
Age range: 18 Years
🧪 Interventions in This Study
- Pharmacist-Led (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (5 Sites)
- Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE — Omaha, Nebraska
- VA Portland Health Care System, Portland, OR — Portland, Oregon
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA — Philadelphia, Pennsylvania
- VA Salt Lake City Health Care System, Salt Lake City, UT — Salt Lake City, Utah
- VA Puget Sound Health Care System Seattle Division, Seattle, WA — Seattle, Washington
📞 Contact the Study Coordinator
Phone: (402) 995-3206
Email: bridget.kramer@va.gov
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Gout
- Assessing the Role of the NLRP3 Inflammasome in Intercritical Gout — Beverly Hills, California
- Gout in the ED and Improving Research Participation — Birmingham, Alabama
- Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients — Margate, Florida
- Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001. — Sacramento, California
- PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function — Tampa, Florida
- Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301) — Birmingham, Alabama
Explore by condition: All Gout clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.